Portal de Periódicos da CAPES

Vaccine effectiveness against COVID-19 breakthrough infections in patients with cancer (UKCCEP): a population-based test-negative case-control study

2022; Elsevier BV; Volume: 23; Issue: 6 Linguagem: Inglês

10.1016/s1470-2045(22)00202-9

1474-5488

Lennard Y. W. Lee, Thomas Starkey, Maria C. Ionescu, Martin Little, Michaël Tilby, Arvind Tripathy, Hayley McKenzie, Youssra Al-Hajji, Matthew Barnard, Liza Benny, Alexander Burnett, Emma Cattell, Jackie Charman, James J. Clark, Sam Khan, Q. Ghafoor, George Illsley, Catherine Harper‐Wynne, Rosie Hattersley, Alvin Lee, Pauline Leonard, Justin K. H. Liu, Matthew Pang, Jennifer Pascoe, James R. Platt, Vanessa Potter, Amelia Randle, Anne Rigg, Tim Robinson, Tom Roques, René L. Roux, Stefan Rozmanowski, Mark Tuthill, Isabella Watts, Sarah Williams, Timothy Iveson, SM Lee, Gary Middleton, Mark R. Middleton, Andrew Protheroe, Matthew W. Fittall, Tom Fowler, Peter Johnson, Emma Kinloch, Emily Lam, Gillian Murphy, Malcolm Rhodes, Kate Robinson,

Vaccine Coverage and Hesitancy

People with cancer are at increased risk of hospitalisation and death following infection with SARS-CoV-2. Therefore, we aimed to conduct one of the first evaluations of vaccine effectiveness against breakthrough SARS-CoV-2 infections in patients with cancer at a population level.